Introduction

One of the main lines of research of the group is the epidemiology of hematological neoplasms, with the aim of determining the incidence, prevalence and survival of this type of cancer. The results obtained aim to provide useful and reliable information to design and/or improve the appropriate health resources and describe the population trends of this group of diseases.

Our Research

Hematological neoplasms are a large group of diseases with a wide variability derived mainly from the type of cells that cause it. Also, the evolution and prognosis of each histological subtype of neoplasia is very diverse and it is necessary to deepen the knowledge of each of them. In this sense, population cancer records are a reference tool for establishing the incidence and survival of each type.

Our Goals

Specifically, our research objectives aim at:

1. Establishing the prevalence, incidence and survival of myeloid, lymphoid and histiocytosis neoplasms globally and according to the respective subtypes.

2. To analyze the temporal trend of the incidence and survival of hematological neoplasms in the context of the evolving therapeutic background.

3. Determine epidemiological parameters based on sex and age.

4. Carry out etiological studies of hematological neoplasms according to each of the histological subtypes.

5. To study the genetic and environmental risk factors related to hematological neoplasms.

6. Describe the risk factors and epidemiology of multiple myeloma based on its precursor cells.

7. Analyze the associations between comorbidity and the survival of lymphoid and myeloid neoplasms.

8. Evaluate the population effectiveness of new therapies in a real population and the impact on survival.

9. Identify changes in the classification, definition and coding of hematological neoplasms and establish working protocols to have homogeneous tools that allow epidemiological comparisons at the international level.

Our Challenges

Through our research, we aim to understand the following:

1. What is the incidence of hematological neoplasms in the territory?

2. What is the survival of each of the histological subtypes of neoplasia?

3. How have changes in the coding of hematological neoplasms over time affected the epidemiological determinants of this group of diseases?